Laddar...
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
BACKGROUND: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve l...
Sparad:
| I publikationen: | J Immunother Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6062934/ https://ncbi.nlm.nih.gov/pubmed/30053905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0387-x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|